Navigation Links
Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
Date:5/12/2010

CALGARY, May 12 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended March 31, 2010.

"We have recently seen a range of preclinical and clinical results that both improved our understanding of REOLYSIN(R)'s mechanism of action and provided evidence of synergies with currently approved therapeutics in an expanded range of potential indications," said Dr. Brad Thompson, President and CEO of Oncolytics. "While much of this information will support future decisions with respect to our evolving clinical program, our near term focus will be on completing the final preparations to begin enrollment in our Phase III trial which we expect to begin in the second quarter."

    Selected Highlights
    -------------------

    Since January 1, 2010 the Company announced:

    Clinical Trial Results

    -   A poster presentation, entitled "Reovirus replication in ovarian and
        peritoneal tumors after intravenous administration," covering
        correlative results from a Phase 1/2 study with reovirus, sponsored
        by the National Cancer Institute under its Clinical Trials Agreement
        with Oncolytics, in patients with ovarian, primary peritoneal and
        fallopian tube carcinoma, was presented at the 101st AACR Annual
        Meeting in Washington, DC. The authors reported that when REOLYSIN is
        administered intravenously, the reovirus can be demonstrated to
        localize and replicate in ovarian and peritoneal tumors;

    Clinical Program

    -   Approval from the U.K. Medicines and Healthcare products Regulatory
        Age
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ... Bina Technologies, Inc. (Bina), a privately held company ... , USA. Bina provides a big data platform ... sequencing (NGS) data. Bina,s proprietary on-market Genomic Management ... academic researchers to perform fast and scalable analyses ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... VALENCIA, Calif., Nov. 20 MannKind,Corporation (Nasdaq: MNKD ... and cancer, announced today that it,will present at the ... AM ET at the Pierre Hotel in New York, ... the live web cast of the,presentation in the Investor ...
... Nov. 20 Sports and,nutritional product manufacturer, Natural ... announced today that it has,launched an international marketing ... Relief Cream. Made from a combination of,botanical and ... the internet and television. Natural Nutrition,s BLUE ...
... Nov. 20 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ... developing, manufacturing and marketing biopharmaceutical,products, announces today that ... the 19th Annual Piper Jaffray Health Care Conference ... November 27, 2007 at 4:30 P.M. EST. ...
Cached Biology Technology:Natural Nutrition Launches International Marketing Campaign for New All Natural Analgesic: BLUE LIGHTNING(TM) Fast Pain Relief 2
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ... functional endpoints to toxicology studies has evolved from ...
(Date:12/10/2014)... 2014 CIE San Diego has launched an ... connective tissue that enhances care coordination among social service ... client-level information; earned a second $1 million grant from ... seniors aging in community and; will be recognized as ... th 4-6p. CIE San Diego today ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... has profound implications for where evangelicals fit into the ... Rice University and the University of Texas-Austin. "In ... Sen. Obama can shave off enough evangelical votes to ... one of the researchers. "That depends a great deal ...
... at the University of York have discovered a ,Chemical ... Hemisphere from the largely uncontaminated atmosphere of the Southern ... found evidence for an atmospheric chemical equator around 50 ... Their findings show for the first time that the ...
... genetic disorder called tuberous sclerosis complex (TSC) is yielding ... structural abnormalities in neurons, or brain cells. Researchers in ... led by Mustafa Sahin, MD, PhD, and Xi He, ... be restored. If this could be done ...
Cached Biology News:New study looks to define evangelicals and how they affect polling 2'Chemical equator' discovery will aid pollution mapping 2Rare genetic disorder gives clues to autism, epilepsy, mental retardation 2
The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
... Physical Form: buffered aqueous solution. ... terminal galactose from complex carbohydrates and glycoproteins. ... galactose under conditions where the pH must ... live cells. Unit Definition: ...
... is specific for human cardiac troponin subunit T, ... signals responsible for contraction of cardiac muscle. It ... in human cells. It also cross-reacts with human ... Antigen: Highly purified human cardiac troponin ...
cystatin A (N-18)...
Biology Products: